Browse our anti-IL27 Receptor alpha (IL27RA) Antibodies

Human Interleukin 27 Receptor, alpha (IL27RA) interaction partners

1. this study found elevated expression of IL-27 (show IL27 Antibodies) in human peripheral serum and elevated expression of its specific receptor (wsx-1) on fetal membranes in cases of preterm birth

2. These results identify IL-27 (show IL27 Antibodies) and its specific receptor IL27RA as a critical immune axis for the antiviral immune response and as robust correlates of viral load and proviral reservoir size in mononuclear leukocytes in HIV infection.

3. Findings demonstrated that IL-27 (show IL27 Antibodies) and IL-27R were elevated in multiple sclerosis lesions and that local IL-27 (show IL27 Antibodies) can modulate immune properties of astrocytes and infiltrating immune cells

4. The significant expression of IL-27 (show IL27 Antibodies) in TB and the negative influence of IL-27R on T cell function demonstrate the pathway by which this cytokine/receptor (show EBI3 Antibodies) pair is detrimental in TB.

5. natural sIL (show PMEL Antibodies)-27Ralpha binds rIL (show PDLIM4 Antibodies)-27, inhibits IL-27 (show IL27 Antibodies) binding to its cell surface receptor, and is a potent inhibitor of IL-27 (show IL27 Antibodies) signaling, as shown by its ability to specifically block IL-27 (show IL27 Antibodies)-mediated STAT (show STAT1 Antibodies) activation, at low molar excess over IL-27 (show IL27 Antibodies).

6. Aberrant hypermethylation and reduced expression of IL27RA is associated with myelodysplastic syndromes.

7. TCCR/WSX-1 is closely associated with angiogenesis and could serve as a novel therapeutic target in patients with age-related macular degeneration.

8. Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity.

9. WSX-1 is essential for transcriptional activation of STAT1 (show STAT1 Antibodies) and for augmenting the induction of T-bet expression during initiation of Th1 (show TH1L Antibodies) cell differentiation.

10. WSX-1 together with the cytokine receptor (show EBI3 Antibodies) gp130 (show IL6ST Antibodies) constitutes a functional signal-transducing receptor for IL-27 (show IL27 Antibodies).

Mouse (Murine) Interleukin 27 Receptor, alpha (IL27RA) interaction partners

1. The combination of mutant p53 (show TP53 Antibodies) & IL27RA(-/-) causes spontaneous liver inflammation, steatosis, and fibrosis, whereas either gene alone has no effects on the liver.

2. IL-10 (show IL10 Antibodies) production by CD4 (show CD4 Antibodies)(+) YFP(+) T cells is controlled systemically during malaria infection through IL-27 (show IL27 Antibodies) receptor signaling that is supported after CD4 (show CD4 Antibodies)(+) T cell priming by ICOS (show ICOS Antibodies) signaling.

3. The significant expression of IL-27 (show IL27 Antibodies) in TB and the negative influence of IL-27R on T cell function demonstrate the pathway by which this cytokine/receptor (show LEPR Antibodies) pair is detrimental in TB.

4. IL-27R-mediated regulation of IL-17 (show IL17A Antibodies) controls the development of respiratory syncytial virus-associated pathogenesis.

5. CCL4 and CCL5 expression was higher in livers of infected WSX-1(-/-) mice than infected WT mice, and hepatic CD4 T cells from WSX-1(-/-) mice expressed higher levels of CCR5 than cells from WT mice

6. The loss of IL-27R signaling across the whole mouse resulted in reduced viral control and a slight increase in the number of virus-specific CD4 (show CD4 Antibodies) T cells at early stages of viral infection.

7. Diminution of the Th1 response in infected Il27ra mice in vivo by neutralization of IL-12p40 attenuated CCR5 expression.

8. These findings establish a novel antiatherogenic role for IL-27 (show IL27 Antibodies) receptor signaling, which acts to suppress the production of proinflammatory cytokines and chemokines and to curb the recruitment of inflammatory myeloid cells into atherosclerotic aortas.

9. In Th1 (show HAND1 Antibodies)-dependent autoinflammatory lesions, IL-27Ralpha has a biphasic role in vivo, initially pathogenic, but ultimately playing a protective role by regulating immune responses and attenuating disease.

10. Data show that the deletion of Il27ra ameliorates pathology in the pristane-induced SLE model.